482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Teprotumumab Prostate Cancer	Shanghai Changzheng Hospital	Early P1	C (32)
Magrolimab Prostate Cancer	National Cancer Institute (NCI)	P1	D (30)
Oxybutynin Prostate Cancer	National Taiwan University Hospital	N/A	D (30)
Unicar02-T Prostate Cancer	AvenCell Therapeutics, Inc.	P1	D (30)
(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine Prostate Cancer	Nuvation Bio Inc.	P1/2	D (28)
68Ga-PSMA-33 Prostate Cancer	Nanjing First Hospital, Nanjing Medical University	N/A	D (26)
Pravastatin Prostate Cancer	McMaster University	N/A	D (26)
161tb-lnc1011 Prostate Cancer	Peking Union Medical College Hospital	Early P1	NR ()
177lu-fc516 Prostate Cancer	FindCure Biosciences (ZhongShan) Co., Ltd.	Early P1	NR ()
[177lu]lu-psma-137 Prostate Cancer	Peking University First Hospital	Early P1	NR ()
89sr Prostate Cancer	Zhujiang Hospital	N/A	NR ()
99mTc-QULIC-5-P1 Prostate Cancer	First Affiliated Hospital of Chongqing Medical University	Early P1	NR ()
Cu-Nu101 Prostate Cancer	Hoag Memorial Hospital Presbyterian	P2	NR ()
dec003m Prostate Cancer	Hangzhou DAC Biotechnology Co., Ltd.	P1	NR ()
glr2037 Prostate Cancer	Gan & Lee Pharmaceuticals.	P1	NR ()
Hrs-1738 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1/2	NR ()
Poly-Iclc Intramuscular Prostate Cancer	Ashutosh Kumar Tewari	P2	NR ()
qlf4113 for Prostate Cancer	Qilu Pharmaceutical Co., Ltd.	P1	NR ()
qlg1080 Prostate Cancer	Qilu Pharmaceutical Co., Ltd.	P3	NR ()
Terbium 161- Psma I&T Prostate Cancer	Ankara University	P2	NR ()
Turmeric Prostate Cancer	University of Arkansas	P1	NR ()

Showing 451 to 482 of 482 assets

PreviousPage 10 of 10Next